Dr Inge Marie Svane speaks to ecancer about the phase 3 clinical findings of IO102-IO103, an investigational immune-modulatory cancer vaccine designed to enhance anti-tumour immunity by targeting IDO1+ and PD-L1+ cells within the tumour microenvironment.

Dr Svane explains that the study evaluates IO102-IO103 in combination with pembrolizumab versus pembrolizumab monotherapy in treatment-naive patients with advanced melanoma.

The results of the study show that the combination of IO102-IO103 and pembrolizumab delivered a clinically meaningful 8.4-month improvement in progression-free survival with a favourable safety profile.

Dr Svane says that these results support the potential of this therapeutic vaccine to enhance checkpoint inhibitor efficacy in advanced melanoma without adding systemic toxicity.